المؤلفون: Yap D., Farrell E.

مصطلحات الفهرس: menopausal syndrome/dt [Drug Therapy], menopausal syndrome/et [Etiology], osteolysis, patient counseling, patient referral, prescription, risk benefit analysis, side effect/si [Side Effect], thromboembolism/si [Side Effect], transdermal patch, treatment indication, clonidine/ae [Adverse Drug Reaction], clonidine/cm [Drug Comparison], clonidine/dt [Drug Therapy], clonidine/pd [Pharmacology], conjugated estrogen/ae [Adverse Drug Reaction], conjugated estrogen/ct [Clinical Trial], conjugated estrogen/cb [Drug Combination], conjugated estrogen/cm [Drug Comparison], conjugated estrogen/dt [Drug Therapy], conjugated estrogen/po [Oral Drug Administration], conjugated estrogen/pr [Pharmaceutics], conjugated estrogen plus medroxyprogesterone acetate/ae [Adverse Drug Reaction], conjugated estrogen plus medroxyprogesterone acetate/ct [Clinical Trial], conjugated estrogen plus medroxyprogesterone acetate/ad [Drug Administration], conjugated estrogen plus medroxyprogesterone acetate/cm [Drug Comparison], conjugated estrogen plus medroxyprogesterone acetate/dt [Drug Therapy], conjugated estrogen plus medroxyprogesterone acetate/po [Oral Drug Administration], conjugated estrogen plus medroxyprogesterone acetate/pr [Pharmaceutics], cyproterone acetate/ae [Adverse Drug Reaction], cyproterone acetate/cb [Drug Combination], cyproterone acetate/dt [Drug Therapy], cyproterone acetate/po [Oral Drug Administration], cyproterone acetate/pr [Pharmaceutics], cyproterone acetate plus estradiol valerate, dydrogesterone/ae [Adverse Drug Reaction], dydrogesterone/cb [Drug Combination], dydrogesterone/dt [Drug Therapy], dydrogesterone/po [Oral Drug Administration], dydrogesterone/pr [Pharmaceutics], dydrogesterone plus estradiol, estradiol/ae [Adverse Drug Reaction], estradiol/ad [Drug Administration], estradiol/cb [Drug Combination], estradiol/dt [Drug Therapy], estradiol/po [Oral Drug Administration], estradiol/pr [Pharmaceutics], estradiol/td [Transdermal Drug Administration], estradiol plus norethisterone acetate/ae [Adverse Drug Reaction], estradiol plus norethisterone acetate/ad [Drug Administration], estradiol plus norethisterone acetate/dt [Drug Therapy], estradiol plus norethisterone acetate/pr [Pharmaceutics], estradiol plus norethisterone acetate/td [Transdermal Drug Administration], estradiol valerate/ae [Adverse Drug Reaction], estradiol valerate/cb [Drug Combination], estradiol valerate/dt [Drug Therapy], estradiol valerate/po [Oral Drug Administration], estradiol valerate/pr [Pharmaceutics], estrofem, estrogen derivative/ae [Adverse Drug Reaction], estrogen derivative/ct [Clinical Trial], estrogen derivative/ad [Drug Administration], estrogen derivative/cb [Drug Combination], estrogen derivative/cm [Drug Comparison], estrogen derivative/dt [Drug Therapy], estrogen derivative/na [Intranasal Drug Administration], estrogen derivative/va [Intravaginal Drug Administration], estrogen derivative/po [Oral Drug Administration], estrogen derivative/pr [Pharmaceutics], estrogen derivative/td [Transdermal Drug Administration], medroxyprogesterone acetate/ae [Adverse Drug Reaction], medroxyprogesterone acetate/ct [Clinical Trial], medroxyprogesterone acetate/ad [Drug Administration], medroxyprogesterone acetate/cb [Drug Combination], medroxyprogesterone acetate/dt [Drug Therapy], medroxyprogesterone acetate/na [Intranasal Drug Administration], medroxyprogesterone acetate/va [Intravaginal Drug Administration], medroxyprogesterone acetate/po [Oral Drug Administration], medroxyprogesterone acetate/pr [Pharmaceutics], medroxyprogesterone acetate/td [Transdermal Drug Administration], norethisterone/ae [Adverse Drug Reaction], norethisterone/dt [Drug Therapy], norethisterone/po [Oral Drug Administration], norethisterone/pr [Pharmaceutics], phytoestrogen/dt [Drug Therapy], phytoestrogen/pk [Pharmacokinetics], piperazine estrone sulfate, progesterone/dt [Drug Therapy], progesterone/ec [Endogenous Compound], progesterone/pr [Pharmaceutics], progesterone derivative/ae [Adverse Drug Reaction], progesterone derivative/ct [Clinical Trial], progesterone derivative/ad [Drug Administration], progesterone derivative/cb [Drug Combination], progesterone derivative/cm [Drug Comparison], progesterone derivative/dt [Drug Therapy], progesterone derivative/na [Intranasal Drug Administration], progesterone derivative/va [Intravaginal Drug Administration], progesterone derivative/po [Oral Drug Administration], progesterone derivative/pr [Pharmaceutics], progesterone derivative/td [Transdermal Drug Administration], propranolol/cm [Drug Comparison], propranolol/dt [Drug Therapy], propranolol/pd [Pharmacology], serotonin uptake inhibitor/dt [Drug Therapy], serotonin uptake inhibitor/pd [Pharmacology], testosterone/ad [Drug Administration], testosterone/cb [Drug Combination], testosterone/dt [Drug Therapy], testosterone/ec [Endogenous Compound], testosterone/po [Oral Drug Administration], testosterone/td [Transdermal Drug Administration], tibolone/cm [Drug Comparison], tibolone/dt [Drug Therapy], tibolone/pk [Pharmacokinetics], tibolone/pd [Pharmacology], trisequens, unclassified drug, venlafaxine/dt [Drug Therapy], venlafaxine/pd [Pharmacology], andro feme cream, catapress 100, climen 28, cyprone, estalis continuous, estracombi, Estraderm MX, femtran, genoral, kliovance, menoprem continuous, natragen cream, oestradiol implants, ovestin tablets, piperazone estrone sulfate/ae [Adverse Drug Reaction], piperazone estrone sulfate/dt [Drug Therapy], piperazone estrone sulfate/po [Oral Drug Administration], piperazone estrone sulfate/pr [Pharmaceutics], premia, premia continuous, pro feme cream, procur, provelle 28, ralovera, medroxyhexal, article, breast cancer/di [Diagnosis], breast cancer/si [Side Effect], cardiovascular disease/dt [Drug Therapy], cardiovascular disease/pc [Prevention], clinical feature, clinical trial, deep vein thrombosis/si [Side Effect], drug absorption, drug efficacy, drug formulation, hormone substitution, human, lifestyle, Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/33104
Click here for full text options
LibKey Link

المؤلفون: Farrell E.

مصطلحات الفهرس: headache/dt [Drug Therapy], hormonal therapy, hot flush/dt [Drug Therapy], human, irritability, libido, lifestyle, long term care, menopausal syndrome/dt [Drug Therapy], menopausal syndrome/th [Therapy], menopause, mood disorder/si [Side Effect], musculoskeletal disease/dt [Drug Therapy], nausea/si [Side Effect], night sweat/dt [Drug Therapy], nutrition, osteoporosis/dt [Drug Therapy], osteoporosis/pc [Prevention], periodontal disease/dt [Drug Therapy], review, risk assessment, side effect/si [Side Effect], smoking, treatment contraindication, treatment indication, urogenital tract disease/dt [Drug Therapy], calcium, clonidine/dt [Drug Therapy], dydrogesterone/dt [Drug Therapy], estradiol/dt [Drug Therapy], estriol/dt [Drug Therapy], estrogen/ae [Adverse Drug Reaction], estrogen/bd [Buccal Drug Administration], estrogen/ad [Drug Administration], estrogen/cb [Drug Combination], estrogen/dt [Drug Therapy], estrogen/im [Intramuscular Drug Administration], estrogen/na [Intranasal Drug Administration], estrogen/ut [Intrauterine Drug Administration], estrogen/va [Intravaginal Drug Administration], estrogen/po [Oral Drug Administration], estrogen/sc [Subcutaneous Drug Administration], estrogen/td [Transdermal Drug Administration], estrone/dt [Drug Therapy], gestagen/ae [Adverse Drug Reaction], gestagen/bd [Buccal Drug Administration], gestagen/ad [Drug Administration], gestagen/cb [Drug Combination], gestagen/dt [Drug Therapy], gestagen/im [Intramuscular Drug Administration], gestagen/na [Intranasal Drug Administration], gestagen/ut [Intrauterine Drug Administration], gestagen/va [Intravaginal Drug Administration], gestagen/po [Oral Drug Administration], gestagen/sc [Subcutaneous Drug Administration], gestagen/td [Transdermal Drug Administration], levonorgestrel/dt [Drug Therapy], medroxyprogesterone acetate/dt [Drug Therapy], norethisterone/dt [Drug Therapy], phytoestrogen, progesterone/dt [Drug Therapy], serotonin uptake inhibitor/dt [Drug Therapy], testosterone/bd [Buccal Drug Administration], testosterone/ad [Drug Administration], testosterone/dt [Drug Therapy], testosterone/im [Intramuscular Drug Administration], testosterone/na [Intranasal Drug Administration], testosterone/ut [Intrauterine Drug Administration], testosterone/va [Intravaginal Drug Administration], testosterone/po [Oral Drug Administration], testosterone/cj [Subconjunctival Drug Administration], testosterone/td [Transdermal Drug Administration], tibolone/dt [Drug Therapy], mood disorder/dt [Drug Therapy], alcohol consumption, alternative medicine, breakthrough bleeding/si [Side Effect], breast cancer, breast disease/si [Side Effect], cancer risk, cognitive defect/dt [Drug Therapy], dementia/dt [Drug Therapy], diabetes mellitus, diet, endometriosis, exercise, fluid retention, Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/32701
Click here for full text options
LibKey Link

المؤلفون: Yap D., Farrell E.

مصطلحات الفهرس: menopausal syndrome/dt [Drug Therapy], menopausal syndrome/et [Etiology], osteolysis, patient counseling, patient referral, prescription, risk benefit analysis, side effect/si [Side Effect], thromboembolism/si [Side Effect], transdermal patch, treatment indication, clonidine/ae [Adverse Drug Reaction], clonidine/cm [Drug Comparison], clonidine/dt [Drug Therapy], clonidine/pd [Pharmacology], conjugated estrogen/ae [Adverse Drug Reaction], conjugated estrogen/ct [Clinical Trial], conjugated estrogen/cb [Drug Combination], conjugated estrogen/cm [Drug Comparison], conjugated estrogen/dt [Drug Therapy], conjugated estrogen/po [Oral Drug Administration], conjugated estrogen/pr [Pharmaceutics], conjugated estrogen plus medroxyprogesterone acetate/ae [Adverse Drug Reaction], conjugated estrogen plus medroxyprogesterone acetate/ct [Clinical Trial], conjugated estrogen plus medroxyprogesterone acetate/ad [Drug Administration], conjugated estrogen plus medroxyprogesterone acetate/cm [Drug Comparison], conjugated estrogen plus medroxyprogesterone acetate/dt [Drug Therapy], conjugated estrogen plus medroxyprogesterone acetate/po [Oral Drug Administration], conjugated estrogen plus medroxyprogesterone acetate/pr [Pharmaceutics], cyproterone acetate/ae [Adverse Drug Reaction], cyproterone acetate/cb [Drug Combination], cyproterone acetate/dt [Drug Therapy], cyproterone acetate/po [Oral Drug Administration], cyproterone acetate/pr [Pharmaceutics], cyproterone acetate plus estradiol valerate, dydrogesterone/ae [Adverse Drug Reaction], dydrogesterone/cb [Drug Combination], dydrogesterone/dt [Drug Therapy], dydrogesterone/po [Oral Drug Administration], dydrogesterone/pr [Pharmaceutics], dydrogesterone plus estradiol, estradiol/ae [Adverse Drug Reaction], estradiol/ad [Drug Administration], estradiol/cb [Drug Combination], estradiol/dt [Drug Therapy], estradiol/po [Oral Drug Administration], estradiol/pr [Pharmaceutics], estradiol/td [Transdermal Drug Administration], estradiol plus norethisterone acetate/ae [Adverse Drug Reaction], estradiol plus norethisterone acetate/ad [Drug Administration], estradiol plus norethisterone acetate/dt [Drug Therapy], estradiol plus norethisterone acetate/pr [Pharmaceutics], estradiol plus norethisterone acetate/td [Transdermal Drug Administration], estradiol valerate/ae [Adverse Drug Reaction], estradiol valerate/cb [Drug Combination], estradiol valerate/dt [Drug Therapy], estradiol valerate/po [Oral Drug Administration], estradiol valerate/pr [Pharmaceutics], estrofem, estrogen derivative/ae [Adverse Drug Reaction], estrogen derivative/ct [Clinical Trial], estrogen derivative/ad [Drug Administration], estrogen derivative/cb [Drug Combination], estrogen derivative/cm [Drug Comparison], estrogen derivative/dt [Drug Therapy], estrogen derivative/na [Intranasal Drug Administration], estrogen derivative/va [Intravaginal Drug Administration], estrogen derivative/po [Oral Drug Administration], estrogen derivative/pr [Pharmaceutics], estrogen derivative/td [Transdermal Drug Administration], medroxyprogesterone acetate/ae [Adverse Drug Reaction], medroxyprogesterone acetate/ct [Clinical Trial], medroxyprogesterone acetate/ad [Drug Administration], medroxyprogesterone acetate/cb [Drug Combination], medroxyprogesterone acetate/dt [Drug Therapy], medroxyprogesterone acetate/na [Intranasal Drug Administration], medroxyprogesterone acetate/va [Intravaginal Drug Administration], medroxyprogesterone acetate/po [Oral Drug Administration], medroxyprogesterone acetate/pr [Pharmaceutics], medroxyprogesterone acetate/td [Transdermal Drug Administration], norethisterone/ae [Adverse Drug Reaction], norethisterone/dt [Drug Therapy], norethisterone/po [Oral Drug Administration], norethisterone/pr [Pharmaceutics], phytoestrogen/dt [Drug Therapy], phytoestrogen/pk [Pharmacokinetics], piperazine estrone sulfate, progesterone/dt [Drug Therapy], progesterone/ec [Endogenous Compound], progesterone/pr [Pharmaceutics], progesterone derivative/ae [Adverse Drug Reaction], progesterone derivative/ct [Clinical Trial], progesterone derivative/ad [Drug Administration], progesterone derivative/cb [Drug Combination], progesterone derivative/cm [Drug Comparison], progesterone derivative/dt [Drug Therapy], progesterone derivative/na [Intranasal Drug Administration], progesterone derivative/va [Intravaginal Drug Administration], progesterone derivative/po [Oral Drug Administration], progesterone derivative/pr [Pharmaceutics], progesterone derivative/td [Transdermal Drug Administration], propranolol/cm [Drug Comparison], propranolol/dt [Drug Therapy], propranolol/pd [Pharmacology], serotonin uptake inhibitor/dt [Drug Therapy], serotonin uptake inhibitor/pd [Pharmacology], testosterone/ad [Drug Administration], testosterone/cb [Drug Combination], testosterone/dt [Drug Therapy], testosterone/ec [Endogenous Compound], testosterone/po [Oral Drug Administration], testosterone/td [Transdermal Drug Administration], tibolone/cm [Drug Comparison], tibolone/dt [Drug Therapy], tibolone/pk [Pharmacokinetics], tibolone/pd [Pharmacology], trisequens, unclassified drug, venlafaxine/dt [Drug Therapy], venlafaxine/pd [Pharmacology], andro feme cream, catapress 100, climen 28, cyprone, estalis continuous, estracombi, Estraderm MX, femtran, genoral, kliovance, menoprem continuous, natragen cream, oestradiol implants, ovestin tablets, piperazone estrone sulfate/ae [Adverse Drug Reaction], piperazone estrone sulfate/dt [Drug Therapy], piperazone estrone sulfate/po [Oral Drug Administration], piperazone estrone sulfate/pr [Pharmaceutics], premia, premia continuous, pro feme cream, procur, provelle 28, ralovera, medroxyhexal, article, breast cancer/di [Diagnosis], breast cancer/si [Side Effect], cardiovascular disease/dt [Drug Therapy], cardiovascular disease/pc [Prevention], clinical feature, clinical trial, deep vein thrombosis/si [Side Effect], drug absorption, drug efficacy, drug formulation, hormone substitution, human, lifestyle, Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/33104
LibKey Link

المؤلفون: Farrell E.

مصطلحات الفهرس: headache/dt [Drug Therapy], hormonal therapy, hot flush/dt [Drug Therapy], human, irritability, libido, lifestyle, long term care, menopausal syndrome/dt [Drug Therapy], menopausal syndrome/th [Therapy], menopause, mood disorder/si [Side Effect], musculoskeletal disease/dt [Drug Therapy], nausea/si [Side Effect], night sweat/dt [Drug Therapy], nutrition, osteoporosis/dt [Drug Therapy], osteoporosis/pc [Prevention], periodontal disease/dt [Drug Therapy], review, risk assessment, side effect/si [Side Effect], smoking, treatment contraindication, treatment indication, urogenital tract disease/dt [Drug Therapy], calcium, clonidine/dt [Drug Therapy], dydrogesterone/dt [Drug Therapy], estradiol/dt [Drug Therapy], estriol/dt [Drug Therapy], estrogen/ae [Adverse Drug Reaction], estrogen/bd [Buccal Drug Administration], estrogen/ad [Drug Administration], estrogen/cb [Drug Combination], estrogen/dt [Drug Therapy], estrogen/im [Intramuscular Drug Administration], estrogen/na [Intranasal Drug Administration], estrogen/ut [Intrauterine Drug Administration], estrogen/va [Intravaginal Drug Administration], estrogen/po [Oral Drug Administration], estrogen/sc [Subcutaneous Drug Administration], estrogen/td [Transdermal Drug Administration], estrone/dt [Drug Therapy], gestagen/ae [Adverse Drug Reaction], gestagen/bd [Buccal Drug Administration], gestagen/ad [Drug Administration], gestagen/cb [Drug Combination], gestagen/dt [Drug Therapy], gestagen/im [Intramuscular Drug Administration], gestagen/na [Intranasal Drug Administration], gestagen/ut [Intrauterine Drug Administration], gestagen/va [Intravaginal Drug Administration], gestagen/po [Oral Drug Administration], gestagen/sc [Subcutaneous Drug Administration], gestagen/td [Transdermal Drug Administration], levonorgestrel/dt [Drug Therapy], medroxyprogesterone acetate/dt [Drug Therapy], norethisterone/dt [Drug Therapy], phytoestrogen, progesterone/dt [Drug Therapy], serotonin uptake inhibitor/dt [Drug Therapy], testosterone/bd [Buccal Drug Administration], testosterone/ad [Drug Administration], testosterone/dt [Drug Therapy], testosterone/im [Intramuscular Drug Administration], testosterone/na [Intranasal Drug Administration], testosterone/ut [Intrauterine Drug Administration], testosterone/va [Intravaginal Drug Administration], testosterone/po [Oral Drug Administration], testosterone/cj [Subconjunctival Drug Administration], testosterone/td [Transdermal Drug Administration], tibolone/dt [Drug Therapy], mood disorder/dt [Drug Therapy], alcohol consumption, alternative medicine, breakthrough bleeding/si [Side Effect], breast cancer, breast disease/si [Side Effect], cancer risk, cognitive defect/dt [Drug Therapy], dementia/dt [Drug Therapy], diabetes mellitus, diet, endometriosis, exercise, fluid retention, Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/32701
LibKey Link